[ad_1]
-Data from the PROLONG Phase 2a proof-of-concept study, ebopiprant (OBE022) for spontaneous preterm delivery will be Electronic poster with mini forum——
Geneva, Switzerland and Boston —— July 2, 2021 -ObsEva SA (NASDAQ stock code:OBSV(6: OBSN), a biopharmaceutical company that develops and commercializes new therapies to improve female reproductive health, today announced the release of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant for oral prostaglandin F2alpha (PGF)2A kind) Antagonist for the treatment of spontaneous preterm birth by the Society for Reproductive Research (SRI) 68day The annual meeting will be held in Boston on a virtual basis from July 6th to 9th 2021.
Introduction details As described below:
title: Randomized, placebo-controlled, proof-of-concept trial of Ebopiprant in the treatment of spontaneous preterm birth (PROLONG)
Abstract logo: W-063
Poster exhibition: Clinical perinatal period
host: Elizabeth Garner, MD, MPH, Chief Medical Officer of ObsEva
meeting date: Wednesday, July 7, 2021
meeting time: 4:00-5:30 p.m. EST
title: The development of the pharmaceutical industry in the treatment of preterm labor: the status quo
Small symposium two: The latest developments in the diagnosis and treatment of preterm birth
host: Elizabeth Garner, MD, MDH, Chief Medical Officer of ObsEva
Meeting date: Thursday, July 8, 2021
Session time5:35-6:00 p.m. EST
The conference link will be provided under the “event calendar” in the investor section of…
The full story on Benzinga.com
[ad_2]
Source link
